Large genetic study uncovers new Alzheimer’s drug targets

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

The study examined genome information from nearly 110,000 people diagnosed with Alzheimer’s and 74,000 others who had a parent with the condition. It compared these against data from 2.6 million people without the disease. This effort identified 127 associated gene locations, 48 of which are new findings.

Related Articles

Illustration of mutated blood cells entering the brain through the blood-brain barrier, linked to Alzheimer's pathology.
Image generated by AI

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

Reported by AI Image generated by AI Fact checked

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Japanese researchers have identified a new seed of the amyloid beta protein. The discovery could lead to early-stage therapy for the neurodegenerative disease.

Reported by AI

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline